All In Biotech

Drug Trial Radar · NCT06473259

Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients

Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Therapy (Alone or in Combination) or Radiotherapy on the Primary Tumor in Combination With Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: Multicenter Observational Study of Patients Undergoing Treatment in Clinical Practice in Italian Hospitals

Last checked: Nov 20, 2026Latest source record: Jun 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

3,000

Planned (sponsor's estimate)

Start

Dec 16, 2016

Primary completion

Dec 2026

Study completion Dec 2028

Sponsor

Lead sponsor
Santa Chiara HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 25, 2024

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
Male only

Summary

As written by the sponsor on the registry.

The aim of this observational study is to evaluate the clinical outcomes of treatment with docetaxel, ARTA (alone or in combination) or with radiotherapy on the primary tumor for mCSPC, in an unselected population, in clinical practice

Conditions

  • Prostate Cancer
  • Hormone Sensitive Prostate Cancer
  • Metastatic Tumor

Interventions

  • DocetaxelDrug

    6 courses of docetaxel 75 mg/sqm iv

  • Apalutamide Oral TabletDrug

    240 mg /daily orally

  • Enzalutamide Oral TabletDrug

    600 mg /daily orally

  • Abiraterone acetate tabletsDrug

    1000 mg /daily orally

  • Darolutamide Oral TabletDrug

    600 mg/daily orally

  • radiotherapyRadiation

    radical radiotherapy on primary tumor

  • TriptorelinDrug

    3,75 mg im/4 w

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. progression free survivalTime frame: From date of treatment start until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Istituto Oncologico Veneto

    Padova, Italy · Recruiting

  • Santa Chiara Hospital

    Trento, Italy · Recruiting

  • Azienda Ospedaliera San Luigi

    Orbassano, Torino, Italy · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.